| Budget Amount *help |
¥121,940,000 (Direct Cost: ¥93,800,000、Indirect Cost: ¥28,140,000)
Fiscal Year 2020: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
Fiscal Year 2019: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
Fiscal Year 2018: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
Fiscal Year 2017: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
Fiscal Year 2016: ¥31,980,000 (Direct Cost: ¥24,600,000、Indirect Cost: ¥7,380,000)
|
|---|
| Outline of Final Research Achievements |
Peptide immunotherapies against tumors exhibit limited tumor-regulatory activities. In this study, we found antigen presentation by tumor endothelial cells (ECs). Tumor ECs present tumor antigen peptides in the context of MHC class II molecules. Th cells which recognize tumor peptides infiltrate into tumor tissues in an antigen-specific manner. Th cells then induce infiltration of a large number of tumor-specific CTLs. A combined immunotherapy using HLA class I and class II-binding peptides exhibited potent tumor-regulatory activity. We, in collaboration with NEC, also developed a state-of the art platform to predict HLA-binding peptides which helps design peptide immunotherapies and identify peptides associated with autoimmune diseases. Finally, suppressive tumor microenvironment was investigated and IL6/soluble IL-6R complex secreted from tumor macrophages was found responsible for inducing upregulation of c-Maf in CD4 T cells thereby blocking differentiation into Th1 cells.
|
